- Investing Ideas
- /
- U.S. Pharmaceuticals & Biotech Top Stock Picks from Analysts
U.S. Pharmaceuticals & Biotech Top Stock Picks from Analysts
Results
455
Companies which are more than 50% undervalued based on analyst price target.
455 companies
Summit Therapeutics
Market Cap: US$15.6b
A biopharmaceutical company, focuses on discovery, development, and commercialization of patient, physician, caregiver, and societal friendly medicinal therapies.
SMMT
US$20.95
7D
9.7%
1Y
-4.3%
BioMarin Pharmaceutical
Market Cap: US$10.3b
A biotechnology company, engages in the development and commercialization of therapies for life-threatening rare diseases and medical conditions in the United States, Europe, Latin America, the Middle East, the Asia Pacific, and internationally.
BMRN
US$53.85
7D
-0.2%
1Y
-23.4%
Moderna
Market Cap: US$9.5b
A biotechnology company, provides messenger RNA medicines in the United States, Europe, and internationally.
MRNA
US$24.49
7D
-7.8%
1Y
-63.4%
Corcept Therapeutics
Market Cap: US$8.8b
Engages in discovery and development of medication for the treatment of severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States.
CORT
US$83.87
7D
4.8%
1Y
81.2%
Revolution Medicines
Market Cap: US$8.2b
A clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers.
RVMD
US$43.92
7D
-1.1%
1Y
-3.2%
Avidity Biosciences
Market Cap: US$6.2b
A biopharmaceutical company, engages in the delivery of RNA therapeutics called antibody oligonucleotide conjugates (AOCs).
RNA
US$42.95
7D
1.4%
1Y
-6.5%
Legend Biotech
Market Cap: US$6.2b
Through its subsidiaries, operates as a biopharmaceutical company that discovers, develops, manufactures, and commercializes novel cell therapies for oncology and other indications in the United States, China, and Europe.
LEGN
US$33.37
7D
-2.1%
1Y
-31.5%
Axsome Therapeutics
Market Cap: US$5.8b
A biopharmaceutical company, develops and delivers novel therapies for the management of central nervous system (CNS) disorders in the United States.
AXSM
US$116.76
7D
-0.6%
1Y
29.9%
Bruker
Market Cap: US$4.7b
Develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally.
BRKR
US$31.04
7D
-5.3%
1Y
-55.1%
Vaxcyte
Market Cap: US$4.4b
A clinical-stage vaccine innovation company, develops conjugate and novel protein vaccines to prevent or treat bacterial infectious diseases.
PCVX
US$33.98
7D
1.5%
1Y
-70.3%
Crinetics Pharmaceuticals
Market Cap: US$4.3b
A clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors.
CRNX
US$45.91
7D
36.2%
1Y
-10.2%
Akero Therapeutics
Market Cap: US$3.8b
Engages in the development of treatments for patients with serious metabolic diseases in the United States.
AKRO
US$47.74
7D
2.9%
1Y
66.4%
ADMA Biologics
Market Cap: US$3.7b
A biopharmaceutical company, develops, manufactures, and markets specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally.
ADMA
US$15.61
7D
-2.6%
1Y
-21.9%
Zai Lab
Market Cap: US$3.5b
A biopharmaceutical company, focuses on discovering, developing, and commercializing products that address medical conditions in the areas of oncology, immunology, neuroscience, and infectious diseases.
ZLAB
US$31.62
7D
-4.6%
1Y
31.0%
Soleno Therapeutics
Market Cap: US$3.5b
A clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases.
SLNO
US$64.96
7D
14.8%
1Y
28.7%
Perrigo
Market Cap: US$3.0b
Provides over-the-counter health and wellness solutions in the United States, Europe, and internationally.
PRGO
US$21.45
7D
3.1%
1Y
-18.2%
Viking Therapeutics
Market Cap: US$2.9b
A clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders.
VKTX
US$25.57
7D
-2.6%
1Y
-59.6%
CG Oncology
Market Cap: US$2.9b
A late-stage clinical biopharmaceutical company, develops and commercializes backbone bladder-sparing therapeutics for patients with bladder cancer.
CGON
US$37.54
7D
1.3%
1Y
-0.5%
Immunovant
Market Cap: US$2.8b
A clinical-stage immunology company, develops monoclonal antibodies for the treatment of autoimmune diseases.
IMVT
US$16.23
7D
4.1%
1Y
-43.1%
Apellis Pharmaceuticals
Market Cap: US$2.8b
A commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutic compounds to treat diseases with high unmet needs.
APLS
US$22.37
7D
-4.8%
1Y
-22.4%
Ultragenyx Pharmaceutical
Market Cap: US$2.8b
A biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Europe, the Middle East, Africa, and the Asia-Pacific.
RARE
US$29.08
7D
-1.3%
1Y
-47.7%
Alvotech
Market Cap: US$2.6b
Through its subsidiaries, develops and manufactures biosimilar medicines for patients worldwide.
ALVO
US$8.34
7D
4.1%
1Y
-29.9%
Amicus Therapeutics
Market Cap: US$2.5b
A biotechnology company, focuses on discovering, developing, and delivering novel medicines for rare diseases in the United States and internationally.
FOLD
US$8.24
7D
-3.9%
1Y
-22.8%
ImmunityBio
Market Cap: US$2.4b
A commercial stage biotechnology company, develops next-generation therapies that bolster the natural immune systems to defeat cancers and infectious diseases.
IBRX
US$2.54
7D
-4.9%
1Y
-31.7%
Catalyst Pharmaceuticals
Market Cap: US$2.4b
A commercial-stage biopharmaceutical company, focuses on developing and commercializing medicines for patients living with rare diseases in the United States.
CPRX
US$19.52
7D
-2.6%
1Y
-1.8%
IDEAYA Biosciences
Market Cap: US$2.4b
A precision medicine oncology company, discovers and develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States.
IDYA
US$26.83
7D
3.5%
1Y
-15.3%
Disc Medicine
Market Cap: US$2.3b
A clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases in the United States.
IRON
US$65.55
7D
6.6%
1Y
33.4%
Beam Therapeutics
Market Cap: US$2.3b
A biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States.
BEAM
US$22.97
7D
-5.9%
1Y
-6.2%
Apogee Therapeutics
Market Cap: US$2.2b
A clinical stage biotechnology company, develops novel biologics for the treatment of atopic dermatitis (AD), asthma, eosinophilic esophagitis (EoE), chronic obstructive pulmonary disease (COPD), and other inflammatory and immunology indications.
APGE
US$38.22
7D
0.7%
1Y
-34.9%
89bio
Market Cap: US$2.2b
A clinical-stage biopharmaceutical company, engages in the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases.
ETNB
US$14.70
7D
-1.1%
1Y
98.6%
Denali Therapeutics
Market Cap: US$2.0b
A biopharmaceutical company, discovers and develops therapeutics to treat neurodegenerative and lysosomal storage diseases.
DNLI
US$13.95
7D
4.7%
1Y
-52.1%
Liquidia
Market Cap: US$1.9b
A biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States.
LQDA
US$21.80
7D
-4.8%
1Y
118.0%
Dyne Therapeutics
Market Cap: US$1.9b
A clinical-stage neuromuscular disease company, focuses on discovering and developing therapeutics for neuromuscular diseases in the United States.
DYN
US$13.15
7D
-2.2%
1Y
-63.4%
Vera Therapeutics
Market Cap: US$1.8b
A clinical stage biotechnology company, focuses on the development and commercialization of transformative treatments for patients with serious immunological diseases.
VERA
US$28.20
7D
8.0%
1Y
-36.2%
Intellia Therapeutics
Market Cap: US$1.8b
A clinical-stage gene editing company, focuses on the development of curative genome editing treatments.
NTLA
US$16.31
7D
-5.5%
1Y
-20.6%
Celldex Therapeutics
Market Cap: US$1.7b
A biopharmaceutical company, engages in developing therapeutic antibodies for patients with severe inflammatory, allergic, autoimmune, and other diseases.
CLDX
US$26.14
7D
5.1%
1Y
-23.1%